ArticleBMC cardiovascular disorders2026
Cumulative estimated glucose disposal rate, atherogenic index of plasma, and incident cardiometabolic multimorbidity: a prospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin resistance and atherogenic dyslipidemia are key interrelated processes in the development of cardiometabolic multimorbidity (CMM). Although estimated glucose disposal rate (eGDR) and atherogenic index of plasma (AIP) have been linked to CMM, whether they provide complementary information when evaluated simultaneously remains unclear.
methodsThis prospective cohort study included 4,215 participants from the China Health and Retirement Longitudinal Study. Cumulative eGDR and cumulative AIP were calculated using repeated measurements from Wave 1 and Wave 3. Participants were followed from Wave 3 to Wave 5 for incident CMM. Cox regression models, restricted cubic splines, interaction analyses, and prognostic performance analyses were performed.
resultsDuring a median follow-up of 5.0 years, 452 participants developed incident CMM. In the mutually adjusted model, each 1-SD increase in cumulative eGDR was associated with a lower risk of incident CMM (HR, 0.57; 95% CI, 0.52-0.63), whereas each 1-SD increase in cumulative AIP was associated with a higher risk (HR, 1.17; 95% CI, 1.06-1.28). Joint analysis further differentiated risk. Compared with participants with high cumulative eGDR and low cumulative AIP, the fully adjusted HRs were 1.50 (95% CI, 1.05-2.14), 2.19 (95% CI, 1.58-3.02), and 3.83 (95% CI, 2.89-5.06) for those with high eGDR and high AIP, low eGDR and low AIP, and low eGDR and high AIP, respectively. Positive additive interaction was observed, whereas multiplicative interaction was not statistically significant. The prognostic contributions of the two indices were unequal. Adding cumulative AIP to a model containing cumulative eGDR resulted in statistically significant but modest improvements in reclassification, whereas adding cumulative eGDR to cumulative AIP produced larger improvements. The model incorporating cumulative eGDR and cumulative AIP also showed better prognostic performance than the corresponding cumulative triglyceride-glucose index (TyG)-AIP model, as reflected by improvements in continuous net reclassification improvement and integrated discrimination improvement. Findings were consistent across subgroup and sensitivity analyses.
conclusionsCumulative eGDR and cumulative AIP were both associated with incident CMM after mutual adjustment and provided complementary risk information. Participants with low cumulative eGDR and high cumulative AIP had the highest CMM risk, with evidence of positive additive interaction. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.